Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2019 Feb 4;216(2):407–418. doi: 10.1084/jem.20181353

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2018 Rodriguez-Laguna et al.

This article is distributed under the terms of an Attribution–Noncommercial–Share Alike–No Mirror Sites license for the first six months after the publication date (see http://www.rupress.org/terms/). After six months it is available under a Creative Commons License (Attribution–Noncommercial–Share Alike 4.0 International license, as described at https://creativecommons.org/licenses/by-nc-sa/4.0/).

PMC Copyright notice

Figure 6. — Rapamycin prevents lymphatic hyperplasia and dysfunction in Prox1-CreER^T2;LSL-Pik3ca^H1047R mice. (A) Schematic that shows when mice were injected with tamoxifen. Prox1-CreER^T2;LSL-Pik3ca^H1047R mice were treated with vehicle or rapamycin (100 μg; 5×/wk) from P43 to P70. Tam, tamoxifen. (B and C) Representative images of ear skin whole-mounts stained with an anti–Lyve-1 antibody. The lymphatic network was hyperplastic in vehicle-treated mice but not in rapamycin-treated mice. (D) Lymphatic vessel index values were significantly higher in vehicle-injected mice (267.7 ± 8.293, n = 3) than in rapamycin-injected mice (156 ± 8.269, n = 7). (E and F) EBD was transported to the iliac lymph nodes in rapamycin-treated mice (n = 7), but not in vehicle-treated mice (n = 4). ****, P < 0.0001, unpaired Student’s t test). Bars, 100 µm.